Abstract:Background: Cell cycle dysregulation characterized by cyclin D1 overexpression is common in mantle cell lymphoma (MCL), while mitotic disorder was less studied. Cell division cycle 20 homologue (CDC20), an essential mitotic regulator, was highly expressed in various tumors. Another common abnormality in MCL is p53 inactivation. Little was known about the role of CDC20 in MCL tumorigenesis and the regulatory relationship between p53 and CDC20 in MCL. Methods: CDC20 expression was detected in MCL patients and MCL cell lines harboring mutant p53 (Jeko and Mino cells) and wild-type p53 (Z138 and JVM2 cells). Z138 and JVM2 cells were treated with CDC20 inhibitor apcin, p53 agonist nutlin-3a, or in combination, and then cell proliferation, cell apoptosis, cell cycle, cell migration and invasion were determined by CCK-8, flow cytometry and Transwell assays. The regulatory mechanism between p53 and CDC20 was revealed by dual-luciferase reporter gene assay and CUT&Tag technology. The anti-tumor effect, safety and tolerability of nutlin-3a and apcin were investigated in vivo in the Z138-driven xenograft tumor model. Results: CDC20 was overexpressed in MCL patients and cell lines compared with their respective controls. The typical immunohistochemical marker of MCL patients, cyclin D1, was positively correlated with CDC20 expression. CDC20 high expression indicated unfavorable clinicopathological features and poor prognosis in MCL patients. In Z138 and JVM2 cells, either apcin or nutlin-3a treatment could inhibit cell proliferation, migration and invasion, and induce cell apoptosis and cell cycle arrest. GEO analysis, RT-qPCR and WB results showed that p53 expression was negatively correlated with CDC20 expression in MCL patients, Z138 and JVM2 cells, while this relationship was not observed in p53-mutant cells. Dual-luciferase reporter gene assay and CUT&Tag assay revealed mechanistically that CDC20 was transcriptionally repressed by p53 through directly binding p53 to CDC20 promoter from - 492 to + 101 bp. Moreover, combined treatment of nutlin-3a and apcin showed better anti-tumor effect than single treatment in Z138 and JVM2 cells. Administration of nutlin-3a/apcin alone or in combination confirmed their efficacy and safety in tumor-bearing mice. Conclusions: Our study validates the essential role of p53 and CDC20 in MCL tumorigenesis, and provides a new insight for MCL therapeutics through dual-targeting p53 and CDC20.

ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation

Abstract 830: ZFP14, a p53 target, suppresses tumor formation by regulating HOXA gene cluster expression

ZNF500 Suppresses the Proliferation of Breast Cancer Cells and Sensitizes Them to Chemotherapy by Stabilizing P53 in a Manner That is Competitive to MDM2

p53 exerts anticancer effects by regulating enhancer formation and activity

Zic1 Is Downregulated Through Promoter Hypermethylation, And Functions As A Tumor Suppressor Gene In Colorectal Cancer

EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.

WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.

The tumor suppressor p53 regulates autophagosomal and lysosomal biogenesis in lung cancer cells by targeting transcription factor EB.

Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network

p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma

p53 negatively regulates Wnt pathway and inhibits the proliferation and invasion of lung cancer cell

TC2N, a novel oncogene, accelerates tumor progression by suppressing p53 signaling pathway in lung cancer

Up-regulation of 14-3-3Z in Lung Cancer and Its Implication as Prognostic and Therapeutic Target

Knockdown of Ubiquitin-Specific Protease 51 Attenuates Cisplatin Resistance in Lung Cancer Through Ubiquitination of Zinc-Finger E-box Binding Homeobox 1

Chitinase 3 like 1 suppresses the stability and activity of p53 to promote lung tumorigenesis

ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3/p53 signaling pathway

ZNF500 abolishes breast cancer proliferation and sensitizes chemotherapy by stabilizing P53 via competing with MDM2

NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling

Silencing of ZNF610 suppresses cell proliferation and migration in lung adenocarcinoma

The novel circSLC6A6/miR-1265/C2CD4A axis promotes colorectal cancer growth by suppressing p53 signaling pathway

ZIC2 Promotes Cancer Stem Cell Traits Via Up-Regulating OCT4 Expression in Lung Adenocarcinoma Cells